European Commission approves Roche’s Tecentriq in combination with Avastin for the treatment of people with the most common form of liver cancer

Matt Turner
Patient Affordability

Stacey Gandler
Brand Nourishment

Matthew Durham
Omnidynamic Marketing

Bud Bilanich
Success Coach

Liz Kane
Impactful Strategy

Amy Giles
Increasing Engagement

Frank Burrell
Scientific Storytelling

David Linetsky
Point-of-Care Marketing

Paul Theisen
Patient Acquisition

Suma Ramadas, PhD
Medical Affairs

Brenda Snow
Authentic Patient Voice

Pat Purcell
Meeting Engagement

Joey Cohen
Medication Adherence

Daniel Sontupe
Market Access